Gut microbiota in nonalcoholic fatty liver disease: a PREDIMED-Plus trial sub analysis

Mostra el registre complet Registre parcial de l'ítem

  • dc.contributor.author Gómez Pérez, Ana María
  • dc.contributor.author Ruiz Limón, Patricia
  • dc.contributor.author Salas Salvadó, Jordi
  • dc.contributor.author Vioque, Jesus
  • dc.contributor.author Corella, Dolores
  • dc.contributor.author Fitó Colomer, Montserrat
  • dc.contributor.author Vidal, Josep
  • dc.contributor.author Atzeni, Alessandro
  • dc.contributor.author Torres-Collado, Laura
  • dc.contributor.author Álvarez-Sala, Andrea
  • dc.contributor.author Martínez, María Ángeles
  • dc.contributor.author Goday Arno, Alberto
  • dc.contributor.author Benaiges Foix, David
  • dc.contributor.author García-Gavilán, Jesús Francisco
  • dc.contributor.author Bernal López, María Rosa
  • dc.contributor.author Moreno Indias, Isabel
  • dc.contributor.author Tinahones Madueño, Francisco José
  • dc.date.accessioned 2024-03-07T07:11:47Z
  • dc.date.available 2024-03-07T07:11:47Z
  • dc.date.issued 2023
  • dc.description.abstract To evaluate the changes in the gut microbiota associated with changes in the biochemical markers of nonalcoholic fatty liver disease (NAFLD) after a lifestyle intervention with the Mediterranean diet. Participants (n = 297) from two centers of PREDIMED-Plus trial (Prevención con Dieta Mediterránea) were divided into three different groups based on the change tertile in the Hepatic Steatosis Index (HSI) or the Fibrosis-4 score (FIB-4) between baseline and one year of intervention. One-year changes in HSI were: tertile 1 (T1) (-24.9 to -7.51), T2 (-7.5 to -1.86), T3 (-1.85 to 13.64). The most significant differences in gut microbiota within the year of intervention were observed in the T1 and T3. According to the FIB-4, participants were categorized in non-suspected fibrosis (NSF) and with indeterminate or suspected fibrosis (SF). NSF participants showed higher abundances of Alcaligenaceae, Bacteroidaceae, Bifidobacteriaceae, Clostridiaceae, Enterobacteriaceae, Peptostreptococcaceae, Verrucomicrobiaceae compared to those with SF. Then, participants were divided depending on the FIB-4 tertile of change: T1 (-89.60 to -5.57), T2 (-5.56 to 11.4), and T3 (11.41 to 206.24). FIB-4 T1 showed a decrease in Akkermansia and an increase in Desulfovibrio. T2 had an increase in Victivallaceae, Clostridiaceae, and Desulfovibrio. T3 showed a decrease in Enterobacteriaceae, and an increase in Sutterella, Faecalibacterium, and Blautia. A relation between biochemical index changes of NAFLD/NASH (HSI and FIB-4) and gut microbiota changes were found. These observations highlight the importance of lifestyle intervention in the modulation of gut microbiota and the management of metabolic syndrome and its hepatic manifestations.
  • dc.description.sponsorship This work was supported by the official Spanish Institutions for funding scientific biomedical research, CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN) and Instituto de Salud Carlos III (ISCIII), through the Fondo de Investigación para la Salud (FIS), which is co-funded by the European Regional Development Fund (three coordinated FIS projects lead by JS-S: PI13/00462, PI16/00501 and PI19/00576; two led by JV: PI17/01441, PI14/01206; three led by AG: PI13/00233, PI16/00533, PI19/00017; and two led by MRBL: PI14/00696 and PI17/00855); the Especial Action Project entitled: Implementación y evaluación de una intervención intensiva sobre la actividad física Cohorte PREDIMED-Plus grant (OBN16PE01) to JS-S; the Recercaixa (number 2013ACUP00194) grant to JS-S. DC obtained grant from the Generalitat Valenciana (PROMETEO 2017/17 and PROMETEO 2021/21) and Grant from the Ministry of Science and Innovation/ISCIII (reference: PI19/00781). Eat2beNICE project (European Union’s Horizon 2020 research and innovation programme under grant agreement No 728018). PRL was supported by a “Sara Borrell” postdoctoral contract (CD19/00216) from the ISCIII-Madrid (Spain), co-financed by the Fondo Europeo de Desarrollo Regional-FEDER. IMI was supported by the “Miguel Servet Type II” program (CPII21/00013) of the ISCIII-Madrid (Spain), co-financed by the FEDER. AMGP was supported by a research contract from Servicio Andaluz de Salud (B-0033–2014). AA-S has received a post-doctoral grant (APOSTD/2020/164) from the Consellería de Innovación, Generalitat Valenciana. MRBL is supported by Miguel Servet II program (CPII/00014) from ISCIII and by Nicolás Monardes program (C1-0005-2020) from Servicio Andaluz de Salud, both cofunded by FEDER funds. This work is partially supported by ICREA under the ICREA Academia programme. Food companies Hojiblanca (Lucena, Spain) and Patrimonio Comunal Olivarero (Madrid, Spain) donated extra virgin olive oil; and the Almond Board of California (Modesto, CA, USA), American Pistachio Growers (Fresno, CA, USA), and Paramount Farms (Wonderful Company, LLC, Los Angeles, CA, USA) donated nuts for the PREDIMED-Pilot study.
  • dc.format.mimetype application/pdf
  • dc.identifier.citation Gómez-Pérez AM, Ruiz-Limón P, Salas-Salvadó J, Vioque J, Corella D, Fitó M, Vidal J, Atzeni A, Torres-Collado L, Álvarez-Sala A, Martínez MÁ, Goday A, Benaiges D, García-Gavilán J, Bernal López MR, Moreno-Indias I, Tinahones FJ. Gut microbiota in nonalcoholic fatty liver disease: a PREDIMED-Plus trial sub analysis. Gut Microbes. 2023 Jan-Dec;15(1):2223339. DOI: 10.1080/19490976.2023.2223339
  • dc.identifier.doi http://dx.doi.org/10.1080/19490976.2023.2223339
  • dc.identifier.issn 1949-0976
  • dc.identifier.uri http://hdl.handle.net/10230/59339
  • dc.language.iso eng
  • dc.publisher Taylor & Francis
  • dc.relation.ispartof Gut Microbes. 2023 Jan-Dec;15(1):2223339
  • dc.relation.projectID info:eu-repo/grantAgreement/EC/H2020/728018
  • dc.rights © 2023 The Author(s). Published with license by Taylor & Francis Group, LLC. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
  • dc.rights.accessRights info:eu-repo/semantics/openAccess
  • dc.rights.uri http://creativecommons.org/licenses/by-nc/4.0/
  • dc.subject.keyword Mediterranean diet
  • dc.subject.keyword Microbiome
  • dc.subject.keyword Hepatic steatosis index
  • dc.subject.keyword Metabolic liver disease
  • dc.subject.keyword The Fibrosis-4 score
  • dc.title Gut microbiota in nonalcoholic fatty liver disease: a PREDIMED-Plus trial sub analysis
  • dc.type info:eu-repo/semantics/article
  • dc.type.version info:eu-repo/semantics/publishedVersion

Col·leccions

Articles (Hospital del Mar Research Institute)
Documents OpenAIRE (Open Access Infrastructure for Research in Europe)